{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brexpiprazole+1+mg", "query": { "intervention": "Brexpiprazole 1 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brexpiprazole+1+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T01:07:58.633Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03198078", "title": "Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Brexpiprazole (OPC-34712)", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 316, "start_date": "2017-06-30", "completion_date": "2023-04-03", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03198078" }, { "nct_id": "NCT04066192", "title": "Brexpiprazole in Alcohol Use Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 250, "start_date": "2020-10-30", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066192" }, { "nct_id": "NCT03033069", "title": "A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stress Disorders, Post-Traumatic" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Brexpiprazole Matching Placebo", "type": "DRUG" }, { "name": "Sertraline Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 336, "start_date": "2017-01-26", "completion_date": "2018-11-12", "has_results": true, "last_update_posted_date": "2021-12-08", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 54, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03033069" }, { "nct_id": "NCT03292848", "title": "Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ADHD", "Autism", "Bipolar I Disorder", "Conduct Disorder", "Oppositional Defiant Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 24, "start_date": "2017-10-10", "completion_date": "2018-05-21", "has_results": false, "last_update_posted_date": "2018-06-12", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03292848" }, { "nct_id": "NCT03287869", "title": "A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar I Disorder", "Acute Mania" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 381, "start_date": "2017-10-24", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 44, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 37 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03287869" }, { "nct_id": "NCT01838681", "title": "Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1986, "start_date": "2013-06", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-08-09", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Flowood", "state": "Mississippi" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838681" }, { "nct_id": "NCT04174365", "title": "Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritability Associated With Autism Spectrum Disorder (ASD)" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 119, "start_date": "2019-10-30", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04174365" }, { "nct_id": "NCT01862640", "title": "A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Agitation Associated With", "Alzheimer's Disease", "Alzheimer's Type", "Mental Disorder", "Nervous System Diseases" ], "interventions": [ { "name": "Brexpiprazole, OPC-34712", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 433, "start_date": "2013-07-11", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 37, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01862640" }, { "nct_id": "NCT04258839", "title": "Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritability Associated With Autism Spectrum Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 95, "start_date": "2020-01-23", "completion_date": "2023-03-16", "has_results": true, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 28, "location_summary": "Dothan, Alabama • Phoenix, Arizona • San Francisco, California + 24 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04258839" }, { "nct_id": "NCT02400346", "title": "Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depression Disorder" ], "interventions": [ { "name": "Adjunct brexpiprazole", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 132, "start_date": "2015-03", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-09-21T01:07:58.633Z", "location_count": 13, "location_summary": "Arcadia, California • Miami, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Smyrna", "state": "Georgia" }, { "city": "O'Fallon", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02400346" } ] }